Live Analyst Rating Changes 8035 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Andrew Brackmann
WB
Andrew Brackmann
William Blair
Wall Street Analyst
★★☆☆☆
#1993
on 13Foresight · ranked by our own returns
47%
Success Rate
+3.8%
Average Return
14 of 30 calls profitable · -0.3% vs benchmark
🔒 3-year track record is Pro. Showing 1-year — upgrade.
📈 Across the calls we could measure, roughly 47% of Andrew Brackmann's ratings turned a profit when each position was held for 1 year — averaging +3.8% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

84 Buy 49 Hold 0 Sell
Andrew's Stock Coverage 22 ratings · 2026-07-14
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return
BDX
Becton Dickinson
 Jul 02, 2026 HOLD Buy
+27.0% avg upside
25 analysts
 — -3.9%
XGN
Exagen
 Jul 02, 2026 HOLD Strong Buy
+181.8% avg upside
10 analysts
 — ·
QDEL
QuidelOrtho
 Jul 02, 2026 HOLD Buy
+117.1% avg upside
13 analysts
 — -6.9%
BFLY
Butterfly Network
 Jun 18, 2026 BUY Strong Buy
-43.9% avg upside
7 analysts
 — -10.3%
ADPT
Adaptive Biotechnologies
 Jun 16, 2026 BUY Strong Buy
+1.2% avg upside
14 analysts
 — +22.3%
DGX
Quest Diagnostics
 Jun 15, 2026 BUY Buy
-17.3% avg upside
33 analysts
 — +3.0%
TEM
Tempus AI, Inc. Class A
 Jun 01, 2026 HOLD Strong Buy
+19.3% avg upside
20 analysts
 — +10.3%
CDNA
CareDx
 May 27, 2026 HOLD Buy
+13.9% avg upside
16 analysts
 — +28.7%
GH
Guardant Health
 May 27, 2026 BUY Strong Buy
-11.5% avg upside
31 analysts
 — +25.5%
NEO
NeoGenomics
 May 27, 2026 HOLD Strong Buy
+11.6% avg upside
17 analysts
 — +47.4%
MDXH
MDxHealth
 May 14, 2026 HOLD Strong Buy
+1356.1% avg upside
8 analysts
 — -51.7%
NTRA
Natera
 May 08, 2026 BUY Strong Buy
-4.5% avg upside
26 analysts
 — +40.5%
OWLT
Owlet
 May 08, 2026 BUY Strong Buy
+83.7% avg upside
10 analysts
 — -1.9%
BLLN
BillionToOne, Inc. Class A
 May 07, 2026 BUY Strong Buy
-1.4% avg upside
8 analysts
 — +37.8%
SERA
Sera Prognostics
 May 07, 2026 BUY Strong Buy
+283.5% avg upside
7 analysts
 — +6.2%
VCYT
Veracyte
 May 06, 2026 BUY Strong Buy
-17.8% avg upside
17 analysts
 — -6.6%
BDSX
Biodesix
 May 05, 2026 BUY Strong Buy
+51.0% avg upside
8 analysts
 — -0.9%
LH
Labcorp Holdings
 Apr 30, 2026 BUY Strong Buy
-5.7% avg upside
36 analysts
 — +8.9%
QGEN
Qiagen
 Apr 28, 2026 HOLD Buy
+0.5% avg upside
24 analysts
$38.00
8.31% Downside
 -3.7%
ABT
Abbott Laboratories
 Jan 23, 2026 BUY Strong Buy
+26.1% avg upside
36 analysts
 — -12.0%
ALDX
Aldeyra Therapeutics
 Oct 01, 2024 BUY Strong Buy
+715.5% avg upside
21 analysts
 — -0.9%
SGHT
Sight Sciences
 Feb 03, 2022 BUY Buy
+52.9% avg upside
13 analysts
 — -21.2%
🔒 17 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Andrew Brackmann — Frequently Asked Questions
How accurate are Andrew Brackmann's stock ratings?
Based on the calls 13Foresight could measure, about 47% of Andrew's ratings were profitable over a one-year hold, with an average return of +3.8% per rating, or -0.3% versus the S&P 500. We score every analyst the same way, from historical prices.
How is Andrew ranked on 13Foresight?
Andrew Brackmann is currently ranked #1993 with a 2-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Andrew cover?
Andrew most recently has ratings on BDX, XGN, QDEL, BFLY, ADPT, DGX, TEM, CDNA, GH, NEO, MDXH, NTRA and 10 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.